Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients

12 Oct 2022

Abstract excerpt

Response to metformin, first-line therapy for type 2 diabetes mellitus (T2DM), exists interindividual variation. Considering that transporters belonging to the solute carrier (SLC) superfamily are determinants of metformin pharmacokinetics, we evaluated the effects of promoter variants in organic cation transporter 1 (OCT1) (SLC22A1 rs628031), OCT2 (SLC22A2 rs316019), multidrug and toxin extrusion protein 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Treatment and Management

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Transport and Resistance Mechanisms

Share to Metabolism, Diabetes, and Cancer

Source

Identifiers

PMID: 36289808
DOI: 10.3390/biomedicines10102546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic PatientsPMID 36289808Read ↗

Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort StudySemantic proximity Read ↗

The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.Semantic proximity Read ↗

Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.Semantic proximity Read ↗

Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.Semantic proximity Read ↗

SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.Semantic proximity Read ↗

Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitusSemantic proximity Read ↗

The Impacts of<i>SLC22A1</i>rs594709 and<i>SLC47A1</i>rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes PatientsSemantic proximity Read ↗

Influence of GLUT2 rs8192675, MATE1 rs2289669, and OCT2 rs316019 Genetic Polymorphism on Metformin Efficacy and Glycemic Control in Type 2 Diabetes Mellitus PatientsSemantic proximity Read ↗

The Influence of OCT3 and MATE2 Genetic Polymorphisms in Poor Response to Metformin in Type 2 Diabetes Mellitus.Semantic proximity Read ↗

Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes.Semantic proximity Read ↗

Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review.Semantic proximity Read ↗

A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 DiabetesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.